" class="no-js "lang="en-US"> MicroTransponder - Medtech Alert
Thursday, October 03, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
MicroTransponder | Pharmtech Focus

MicroTransponder

About MicroTransponder

MicroTransponder
MicroTransponder has developed the Paired Vagus Nerve Stimulation System (Paired VNS™ System) based on decades of neuroscience research. The Paired VNS™ System is designed to treat several neurological conditions. Our initial focus is upper limb deficits among chronic stroke patients.

Related Story

Appointments

 MicroTransponder Raises $53M

MicroTransponder Raises $53M, Appoints New CEO

June 21 2022

MicroTransponder®, Inc. closed an oversubscribed $53 million Series E funding round led by US Venture Partners (USVP), a multi-stage investment […]